Oculis

Recent news

• Rating change
  BofA Securities Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $35
  Market Newswire · 2026/6/1
• Top-performing Hong Kong stocks this week | Lightelligence shares rose more than 21% for the week, with its Scale-up OCS becoming a core growth engine; the company was included in the Stock Connect program this month. Maifeishi gained nearly 21%, upgradin
  Market Newswire · 2026/9/5
• Rating change
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $41
  Market Newswire · 2026/8/7
• Stifel Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/9/28
• Rating change
  Guggenheim Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/8/7
• Company notice
  Trendlines: General Announcement-OCS Expands Mandate of Trendlines Medical - Misgav Ltd. to include Agtech Investments
  SGX · 2016/6/21
• Company notice
  Trendlines: General Announcement-OCS Definitive Approval on Expansion of the Mandate of Trendlines Medical - Misgav Ltd.
  SGX · 2016/10/11
• Rating change
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/8/6
• H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $26
  Market Newswire · 2026/8/25
• Dongtu Technology (300353.SZ): The industrial network communications business segment does not involve OCS optical circuit switching products.
  Gelonghui Finance · 2026/9/23
• Rating change
  TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
  TipRanks · 2026/8/3
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
  TipRanks · 2026/8/10
• Rating change
  Decolite (688205): DCI volume is surging at the right time, and OCS deployment is laying the groundwork for a competitive edge.
  AVIC Securities · 2026/6/16
• H.C. Wainwright Maintains Oculis(OCS.US) With Buy Rating, Raises Target Price to $39
  Market Newswire · 2026/9/18
• Rating change
  J.P. Morgan Maintains Oculis(OCS.US) With Buy Rating, Announces Target Price $23
  Market Newswire · 2026/6/3
• Rating change
  LifeSci Capital Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $41
  Market Newswire · 2026/8/8
• Rating change
  Baird Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $38
  Market Newswire · 2026/6/2
• Rating change
  J.P. Morgan Maintains Oculis(OCS.US) With Buy Rating, Cuts Target Price to $20
  Market Newswire · 2026/8/14
• Rating change
  Needham Maintains Oculis(OCS.US) With Buy Rating, Maintains Target Price $38
  Market Newswire · 2026/8/8
• Rating change
  J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)
  TipRanks · 2026/8/14

Headlines are aggregated automatically and are not independently verified or edited by our team.